Streetbeat News

Stock Prices

DRMA

NCNA

RFL

XCUR

Exicure, Inc. (NASDAQ:XCUR) shares surged over 49% in pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq compliance. Other notable pre-market movers include NuCana plc (NASDAQ:NCNA) with a 94.4% gain due to positive Phase 2 study data, and Dermata Therapeutics, Inc. (NASDAQ:DRMA) rising 73.4%. On the downside, Rafael Holdings, Inc. (NYSE:RFL) fell 40.1% after previous gains.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 10:07 am

RIVN

TSLA

Tesla's Cybertruck significantly boosted EV registrations in the U.S. in July, with Tesla seeing a 1.2% increase in registrations. Despite heavy incentives driving sales, Tesla's dominance in the EV market remains strong, while Rivian saw a slight decline.

Portfolio Pulse from Anan Ashraf

September 16, 2024 | 9:57 am

DJT

Shares of Trump Media & Technology Group Corp (NASDAQ:DJT) rose 4.23% in pre-market trading following an attempted assassination on Donald Trump at his Florida golf club. Trump reassured supporters of his safety, and the suspect was apprehended. The incident is under investigation.

Portfolio Pulse from Pooja Rajkumari

September 16, 2024 | 9:43 am

NTRA

Natera has announced the publication of three new peer-reviewed papers, bringing the total to over 85 publications on its cancer diagnostic test, Signatera. This milestone highlights the growing validation and acceptance of Signatera in the medical community.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:21 am

ADAG

Adagene presented new clinical data at the ESMO Congress for its ADG126 and Keytruda combination, showing improved response rates and survival in certain cancer patients. The combination maintained a favorable safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:17 am

AAPL

Apple is facing lower than expected demand for its iPhone 16 Pro and Pro Max models during the first weekend of pre-orders, according to analyst Ming-Chi Kuo. Despite robust overall sales, the Pro models are underperforming, potentially impacting Apple's revenue projections. The iPhone 16 series, introduced with new AI capabilities, is also facing competition in China, and Apple has increased battery replacement prices for the Pro models.

Portfolio Pulse from Rounak Jain

September 16, 2024 | 9:15 am

VGK

The Eurozone's trade balance for July was reported at 21.2 billion euros, surpassing the estimated 14.9 billion euros but slightly below the prior month's 22.3 billion euros.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:03 am

SSYS

Stratasys has announced a share repurchase program authorizing the buyback of up to $50 million worth of its shares. This move is likely aimed at boosting shareholder value and confidence.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:02 am

STRO

Sutro Biopharma presented updated data from its Phase 1b study of Luvelta in combination with Bevacizumab at ESMO 2024. The combination showed a 56% objective response rate in late-stage ovarian cancer patients, with no new safety signals. The recommended phase 2 dose has been selected, and further expansion is ongoing.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:53 am

BCYC

Bicycle Therapeutics reported promising Phase 1/2 results for its cancer treatments: zelenectide pevedotin, BT5528, and BT7480. Zelenectide pevedotin showed a 45% ORR in metastatic urothelial cancer, while BT5528 and BT7480 demonstrated favorable safety profiles and antitumor activity in advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:51 am